Adenocarcinoma, Colon Neoplasms, Malignant Solid Tumors, Neoplasms
Conditions
Keywords
Vaccine Therapy, Dose-Limiting Toxicity, Maximum Tolerated Dose, Clinical Response, Immune Response, Cancer, Solid Tumor
Brief summary
Background: \- Cancer vaccines are being developed to help teach the body's immune system to attack and destroy cancer cells. A new vaccine being tested targets Brachyury protein. This protein is present in some tumor cells, and it can help tumor cells spread to other parts of the body. Researchers want to see whether the new Brachyury protein vaccine can help treat people with advanced carcinomas. Objectives: \- To test the safety and effectiveness of a cancer vaccine that targets Brachyury protein in tumor cells. Eligibility: * Individuals at least 18 years of age who have advanced cancers that have not responded or are no longer responding to standard treatments. * Because the vaccine is made with yeast, people with yeast allergies will not be eligible. Design: * Participants will be screened with a medical history and physical exam. Imaging studies will be used to examine the cancer. Heart and thyroid function tests will be conducted. Blood and urine samples will also be collected. * Participants will receive vaccine injections every 2 weeks, for a total of seven visits. After seven visits, if the cancer has shrunk or stopped growing, participants will continue to have the vaccine about once a month. * Treatment will be monitored with frequent blood tests and imaging studies. Other tests will be given as directed by the study doctors. Some participants will have apheresis to collect additional blood cells for study. * Participants will continue to receive the vaccine as long the tumor does not start growing again and there are no serious side effects....
Detailed description
Background: * Vaccines based on recombinant heat inactivated yeast have been shown to be immunogenic and well tolerated in animals and humans. * Using a computer-based differential display analysis tool to conduct global comparison of expressed sequence tag (EST) clusters in the Unigene database, the gene encoding for the transcription factor Brachyury was identified as highly represented in tumor-derived libraries and rarely observed in normal tissue-derived libraries. By using reverse-transcription followed by polymerase chain reaction (RT-PCR), investigators in the LTIB have identified the overexpression of Brachyury in gastrointestinal, bladder, kidney, ovary, uterus, and testicular carcinomas. Similar studies also found over-expression of Brachyury mRNA in cell lines of lung, colon and prostate cancers, but not in the majority of normal tissues tested, with the exception of expression in the testis, thyroid and low levels of expression in B cells pooled from multiple normal donors. * Brachyury is a member of the T-box family of transcription factors, characterized by a highly conserved DNA-binding domain designated as T-domain. Data indicates that the transcription factor Brachyury confers on the tumor cells a mesenchymal phenotype, as well as migratory and invasive abilities and enhances tumor cell progression. * A murine model of MC38 cells engineered to over express human Brachyury gene has demonstrated increased metastatic potential of Brachyury over-expressing MC38 cells. * Brachyury specific T cells can lyse human cancer cells expressing Brachyury in an MHC restricted manner. * GI-6301 (Yeast-Brachyury vaccine) has been tested in vitro and in the mouse model. These studies showed Brachyury-specific T cell responses and decreased metastasis in mice treated with vaccine. * An ongoing study of a Hepatitis B vaccine (GS-4774) using the yeast platform (heat killed Saccharomyces cerevisiae) indicated safety of 80 YU dose (4 injection sites at 20 YU injections per site). Objectives: -The primary objectives are to: * Determine the safety and tolerability of escalating doses of GI-6301 (Yeast-Brachyury vaccine) a heat-killed yeast-based vaccine * Determine in an expanded cohort if a significant change in Brachyury specific T cells will be detectable post vaccine. Eligibility: * Adults with histologically proven metastatic or locally advanced solid tumors for which standard curative or palliative measures are no longer effective. Efforts will be made, as much as possible, to enroll patients with tumor types with known increased expression of Brachyury (such as lung, breast, ovarian, prostate, colorectal, pancreatic or chordoma). * Adequate organ function as defined by liver, kidney, and hematologic laboratory testing. * Patients with acquired immune defects, systemic autoimmune disease, concurrent use of steroids, pericardial mass \> 1 cm, chronic infections, concurrent tricyclic antidepressant therapy, or allergy to yeast or yeast-based products will be excluded. Design: * This is an open label, phase I trial with sequential dose escalation cohorts of patients (3-6 patients per dose cohort) for 3 doses of GI-6301 (Yeast-Brachyury vaccine). * GI-6301 (Yeast-Brachyury vaccine) will be administered subcutaneously at 4 sites biweekly for 7 visits (day 1, 15, 29, 43, 57, 71, 85), then monthly until patients meet off-study criteria (patients who have been on study for one year or more and have had stable disease or better (PR, CR) have the option to receive vaccine once every 3 months instead of monthly). * All patients on a given dose level will have completed 28 days on-study without DLT before enrollment can begin on the next dose level or on the expansion phase (see statistical analysis section). * Expansion Phase: 10 additional patients will be enrolled on the MTD dose level (or the highest dose level explored in the event that a true MTD is not reached), receiving the same treatment regimen, to assess for immunologic responses and clinical responses. * Amended dose escalation: 10 patients will be enrolled at an additional dose level (80 YU per dose, 4 injection sites at 20 YU per site) to determine the safety of this dose level. * Up to 33 total patients may be required to complete enrollment of this study.
Interventions
BIOLOGICALGI-6301 (Yeast Brachyury Vaccine)
GI-6301 is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
Sponsors
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 100 Years
Healthy volunteers
No
Inclusion criteria
* INCLUSION CRITERIA: Participants must meet the following criteria for participation: * Diagnosis: Patients must have histologically confirmed malignancy by the Laboratory of Pathology, National Cancer Institute (NCI), that is metastatic or unresectable locally advanced malignant solid tumor. In the case of Chordoma, unresectable, locally recurrent, or metastatic tumors are acceptable for enrollment, given that this represents incurable disease. Efforts will be made, as much as possible, to enroll patients with tumor types with known increased expression of Brachyury (such as lung, breast, ovarian, prostate, colorectal, pancreatic, or chordoma). * Patients may have disease that is measurable or non-measurable but evaluable disease * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at study entry (Karnofsky greater than or equal to 70) * Age greater than or equal to 18 years. Because no dosing or adverse event data are currently available on the use of Yeast Brachyury vaccine in patients \<18 years of age, children are excluded from this study, but will be eligible for future pediatric trials. * Prior Therapy: Completed or had disease progression on at least one prior line of diseaseappropriate therapy for metastatic disease, or not be a candidate for therapy of proven efficacy for their disease. * Patients must have normal organ and marrow function as defined below: * Serum creatinine 1.5 times upper limit of normal OR creatinine clearance on a 24-h urine collection of 60 mL/min. * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) 2.5 times the upper limits of normal. * Total bilirubin less than or equal to 1.5 times upper limit of normal OR in patients with Gilbert's syndrome, a total bilirubin 3.0. * Hematological eligibility parameters (within16 days of starting therapy): * Granulocyte count 1,500/mm(3) * Platelet count 100,000/m(3) * Patients must have baseline pulse oximetry \> 90% on room air. * Recovered completely (Grade 1 or baseline) from any reversible toxicity associated with recent therapy. Typically this is 3 4 weeks for patients who most recently received cytotoxic therapy, except for the nitrosoureas and mitomycin C for which 6 weeks is needed for recovery. * There should be a minimum of 2 weeks from any prior chemotherapy, immunotherapy and/or radiation. * Prior immune therapy is allowed. * Men and women of child-bearing potential must agree to use effective birth control or abstinence during and for a period of 4 months after the last vaccination therapy. * Patients with prostate cancer must continue to receive gonadotropin-releasing hormone (GnRH) agonist therapy (unless orchiectomy has been done). If a patient has refused GnRH therapy, they may be enrolled on a dose level for which the safety has already been determined. * Patients with estrogen-receptor positive (ER+) breast cancer being treated with adjuvant hormonal therapy (selective estrogen receptor modulator or aromatase inhibitor) who have rising tumor markers as evidence of disease progression or metastatic disease on scans may continue on hormonal therapy while being treated with vaccine. * Patients must be negative for yeast allergy skin test * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
Patients with any of the following will not be eligible for participation in this study: \- Patients should have no evidence of immune dysfunction as listed below. * Human immunodeficiency virus (HIV) positivity due to the potential for decreased immune response to the vaccine. * Active autoimmune diseases requiring treatment or a history of autoimmune disease that might be stimulated by vaccine treatment. This requirement is due to the potential risks of exacerbating autoimmunity. However, patients with vitiligo, diabetes mellitus, and hashimoto s thyroiditis on appropriate replacement therapy may be enrolled. --Concurrent use of systemic steroids, except for physiologic doses of systemic steroid replacement or local (topical, nasal, or inhaled) steroid use. Limited doses of systemic steroids (e.g., in patients with exacerbations of reactive airway disease or to prevent intravenous (IV) contrast allergic reaction or anaphylaxis in patients who have known contrast allergies) are allowed. * History of allergy or untoward reaction to yeast-based products (any hypersensitivity to yeast-based products will be excluded). * Pregnant or breast-feeding women, due to the unknown effects of the Yeast Brachyury vaccine on the fetus or infant. * Serious intercurrent medical illness which would interfere with the ability of the patient to carry out the treatment program, including, but not limited to, inflammatory bowel disease, Crohn's disease, ulcerative colitis, or active diverticulitis. * Untreated brain metastases (or local treatment of brain metastases within the last 6 months) and or spinal cord metastasis. * Patients with pericardial masses \>1 cm will be excluded. * Concurrent chemotherapy. (However, the following anti-tumor therapies will be allowed: Trastuzumab for human epidermal growth factor receptor 2 (HER2+) breast cancer and hormonal therapy for breast (e.g., selective estrogen receptor modulators, aromatase inhibitors) and prostate cancer (e.g., GnRH antagonists/agonists or antagonists and androgen receptor antagonists). * Chronic hepatitis infection, including B and C, because potential immune impairment caused by these disorders may diminish the effectiveness of this immunologic therapy. * Patients requiring continuous tricyclic antidepressant therapy should be excluded due to the interference with the yeast skin test in creating false negative test results. * Participation in another interventional clinical trial within 28 days before start of study treatment. * Any significant disease that, in the opinion of the investigator, may impair the patient s tolerance of study treatment. * Significant dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Brachyury-Specific T-cell Responses | Baseline (pre-vaccination) and approximately day 84 (after 6 vaccinations) | A fluorescense activated cell sorting (FACS)-based assay for cluster of differentiation 4 (CD4) or cluster of differentiation 8 (CD8) T-cells expressing the cytokines interferon (IFN) gamma, interleukin 2 (IL2), and tumor necrosis factor (TNF) alpha, and/or cluster of differentiation 107a (CD107a) (a marker for lytic potential) was used to determine the numbers of participants showing development or enhancement of the level of brachyury-specific T-cells after vaccination. |
| Count of Participants With Adverse Events of Escalating Doses of Yeast Brachyury ( GI- 6301) Vaccine | 4 years and 25 days | Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. A non-serious adverse event is any untoward medical occurrence. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Changes in Serum Levels of Cytokines | Pre (Baseline) and Day 85 after 6 vaccinations | Blood samples were collected and changes in serum levels of cytokines interferon gamma (IFNg), Interleukin 10 (IL-10), Interleukin 12 (IL-12)p70, Interleukin 1b (IL-1b), Interleukin 2 (IL-2), Interleukin 6 (IL-6), Interleukin 8 (IL-8), and tumor necrosis factor (TNF) were assessed by the multiplexed mesoscale assay. Significance of changes in serum levels of cytokines was determined by p value (Wilcoxon test) and the median and interquartile range of data. |
| Changes in Soluble Cluster of Differentiation 27 (sCD27) | Pre (Baseline) and Day 85 after 6 vaccinations | Blood samples were collected and changes in serum levels of soluble sCD27 were assessed by enzyme-linked immunosorbent assay (ELISA). Significance of changes in soluble sCD27 was determined by p value (Wilcoxon test) and the median and interquartile range of data. |
| Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | 3 and 5 months restaging | Clinical benefit is defined as partial response (PR) or stable disease (SD) and was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Partial response is ≥30% decrease in the sum of greatest diameters/no new lesions. Progressive disease is ≥20% increase in the sum of greatest diameters/new lesions. Stable disease does not meet criteria for complete response (disappearance of all lesions; no new lesions), partial response, or progressive disease. |
| Changes in Soluble Cluster of Differentiation 40L (sCD40L) | Pre (Baseline) and Day 85 after 6 vaccinations | Blood samples were collected and changes in serum levels of soluble sCD27 were assessed by enzyme-linked immunosorbent assay (ELISA). Significance of changes in soluble sCD40L was determined by p value (Wilcoxon test) and the median and interquartile range of data. |
| Median Ratio of Soluble Cluster of Differentiation 27:40L (sCD27:sCD40L) | Pre (Baseline) and Day 85 after 6 vaccinations | Blood samples were collected and changes in serum levels of the ratio of soluble sCD27:sCD40L was assessed by enzyme-linked immunosorbent assay (ELISA). Significance of changes in soluble sCD27:sCD40L was determined by p value (Wilcoxon test) and the median and interquartile range of data. |
| Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Pre (Baseline) and Day 85 after 6 vaccinations | Blood samples will be collected via apheresis and analyzed by multicolor flow cytometry in PBMCs for cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), Natural Killer (NK), Natural Killer T (NKT), conventional dendritic cell (cDC), plasmacytoid dendritic cell (pDC), myeloid-derived suppressor cell (MDSC), Tregs, CD4 central memory (CD4 CM), CD4 effector memory (CD4 EM), CD4 terminal effector memory (CD4 EMRA), CD4 naïve, CD8 CM, CD8 EM, CD8 EMRA, and CD8 naïve cells. Significance of changes in immune cells was determined by p value (Wilcoxon test) and the median and interquartile range of data. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| All Participants All participants who received at least one dose of 4YU, 16YU, 40YU or 80YU.
Yeast-Brachyury vaccine will be administered subcutaneously at 4 sites on 7 visits, then monthly until patients meet off-treatment criteria.
GI-6301 (Yeast Brachyury Vaccine): GI-6301 is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product. | 34 |
| Total | 34 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 |
|---|---|---|---|---|---|
| Overall Study | Off study due to infection | 0 | 0 | 0 | 1 |
| Overall Study | Withdrawal by Subject | 1 | 0 | 0 | 0 |
Baseline characteristics
| Characteristic | All Participants |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 10 Participants |
| Age, Categorical Between 18 and 65 years | 24 Participants |
| Age, Continuous | 58 years |
| Disease at Study Entry Carcinomas Progressive disease | 22 Participants |
| Disease at Study Entry Carcinomas Stable disease | 1 Participants |
| Disease at Study Entry Chordomas Progressive disease | 9 Participants |
| Disease at Study Entry Chordomas Stable disease | 2 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 0 | 14 Participants |
| Eastern Cooperative Oncology Group (ECOG) Performance Status 1 | 20 Participants |
| Prior Cytotoxic Regimens 0 | 1 Participants |
| Prior Cytotoxic Regimens 1 regimen | 2 Participants |
| Prior Cytotoxic Regimens 2 regimens | 8 Participants |
| Prior Cytotoxic Regimens ≥3 regimens | 12 Participants |
| Prior Therapy Radiotherapy | 11 Participants |
| Prior Therapy Surgery | 11 Participants |
| Prior Therapy Systemic therapy | 5 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 0 Participants |
| Race/Ethnicity, Customized Mexican, Puerto Rican, Cuban Central or So. Americ | 1 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 33 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 3 Participants |
| Race (NIH/OMB) Black or African American | 1 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 30 Participants |
| Region of Enrollment United States | 34 Participants |
| Sex: Female, Male Female | 15 Participants |
| Sex: Female, Male Male | 19 Participants |
| Tumor Anatomical Location Clival | 3 Participants |
| Tumor Anatomical Location Sacral | 6 Participants |
| Tumor Anatomical Location Spinal | 2 Participants |
| Tumor Type Breast | 5 Participants |
| Tumor Type Chordoma | 11 Participants |
| Tumor Type Colorectal | 11 Participants |
| Tumor Type Lung | 1 Participants |
| Tumor Type Pancreatic | 3 Participants |
| Tumor Type Prostate | 2 Participants |
| Tumor Type Urothelial | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk |
|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 4 | 0 / 3 | 0 / 16 | 0 / 11 |
| other Total, other adverse events | 4 / 4 | 3 / 3 | 16 / 16 | 10 / 11 |
| serious Total, serious adverse events | 0 / 4 | 0 / 3 | 5 / 16 | 6 / 11 |
Outcome results
Primary
Count of Participants With Adverse Events of Escalating Doses of Yeast Brachyury ( GI- 6301) Vaccine
Here is the count of participants with serious and non-serious adverse events assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0). A non-serious adverse event is any untoward medical occurrence. A serious adverse event is an adverse event or suspected adverse reaction that results in death, a life threatening adverse drug experience, hospitalization, disruption of the ability to conduct normal life functions, congenital anomaly/birth defect or important medical events that jeopardize the patient or subject and may require medical or surgical intervention to prevent one of the previous outcomes mentioned. A non-serious adverse event is any untoward medical occurrence.
Time frame: 4 years and 25 days
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| 4 YU (Dose Level 1) | Count of Participants With Adverse Events of Escalating Doses of Yeast Brachyury ( GI- 6301) Vaccine | 4 Participants |
| 16 YU (Dose Level 2) | Count of Participants With Adverse Events of Escalating Doses of Yeast Brachyury ( GI- 6301) Vaccine | 3 Participants |
| 40 YU (Dose Level 3) | Count of Participants With Adverse Events of Escalating Doses of Yeast Brachyury ( GI- 6301) Vaccine | 16 Participants |
| 80 YU (Dose Level 4) | Count of Participants With Adverse Events of Escalating Doses of Yeast Brachyury ( GI- 6301) Vaccine | 10 Participants |
Primary
Number of Participants With Brachyury-Specific T-cell Responses
A fluorescense activated cell sorting (FACS)-based assay for cluster of differentiation 4 (CD4) or cluster of differentiation 8 (CD8) T-cells expressing the cytokines interferon (IFN) gamma, interleukin 2 (IL2), and tumor necrosis factor (TNF) alpha, and/or cluster of differentiation 107a (CD107a) (a marker for lytic potential) was used to determine the numbers of participants showing development or enhancement of the level of brachyury-specific T-cells after vaccination.
Time frame: Baseline (pre-vaccination) and approximately day 84 (after 6 vaccinations)
Population: Sufficient peripheral blood mononuclear cells (PBMCs) were available before and after vaccination from 31 of 34 patients to analyze brachyury-specific CD4 and CD8 T-cell responses.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 4 YU (Dose Level 1) | Number of Participants With Brachyury-Specific T-cell Responses | CD107a + CD8 T-cell response | 0 Participants |
| 4 YU (Dose Level 1) | Number of Participants With Brachyury-Specific T-cell Responses | IFN gamma + CD4 T-cell response | 1 Participants |
| 4 YU (Dose Level 1) | Number of Participants With Brachyury-Specific T-cell Responses | IL2 + CD4 T-cell response | 0 Participants |
| 4 YU (Dose Level 1) | Number of Participants With Brachyury-Specific T-cell Responses | TNF alpha + CD4 T-cell response | 0 Participants |
| 4 YU (Dose Level 1) | Number of Participants With Brachyury-Specific T-cell Responses | IL2 + CD8 T-cell response | 0 Participants |
| 4 YU (Dose Level 1) | Number of Participants With Brachyury-Specific T-cell Responses | IFN gamma + CD8 T-cell response | 0 Participants |
| 4 YU (Dose Level 1) | Number of Participants With Brachyury-Specific T-cell Responses | TNF alpha + CD8 T-cell response | 0 Participants |
| 4 YU (Dose Level 1) | Number of Participants With Brachyury-Specific T-cell Responses | Any T-cell response | 1 Participants |
| 4 YU (Dose Level 1) | Number of Participants With Brachyury-Specific T-cell Responses | CD107a + CD4 T-cell response | 1 Participants |
| 16 YU (Dose Level 2) | Number of Participants With Brachyury-Specific T-cell Responses | IL2 + CD8 T-cell response | 0 Participants |
| 16 YU (Dose Level 2) | Number of Participants With Brachyury-Specific T-cell Responses | CD107a + CD4 T-cell response | 0 Participants |
| 16 YU (Dose Level 2) | Number of Participants With Brachyury-Specific T-cell Responses | TNF alpha + CD4 T-cell response | 1 Participants |
| 16 YU (Dose Level 2) | Number of Participants With Brachyury-Specific T-cell Responses | IL2 + CD4 T-cell response | 0 Participants |
| 16 YU (Dose Level 2) | Number of Participants With Brachyury-Specific T-cell Responses | IFN gamma + CD4 T-cell response | 0 Participants |
| 16 YU (Dose Level 2) | Number of Participants With Brachyury-Specific T-cell Responses | CD107a + CD8 T-cell response | 0 Participants |
| 16 YU (Dose Level 2) | Number of Participants With Brachyury-Specific T-cell Responses | IFN gamma + CD8 T-cell response | 0 Participants |
| 16 YU (Dose Level 2) | Number of Participants With Brachyury-Specific T-cell Responses | Any T-cell response | 1 Participants |
| 16 YU (Dose Level 2) | Number of Participants With Brachyury-Specific T-cell Responses | TNF alpha + CD8 T-cell response | 0 Participants |
| 40 YU (Dose Level 3) | Number of Participants With Brachyury-Specific T-cell Responses | TNF alpha + CD8 T-cell response | 2 Participants |
| 40 YU (Dose Level 3) | Number of Participants With Brachyury-Specific T-cell Responses | CD107a + CD4 T-cell response | 4 Participants |
| 40 YU (Dose Level 3) | Number of Participants With Brachyury-Specific T-cell Responses | CD107a + CD8 T-cell response | 3 Participants |
| 40 YU (Dose Level 3) | Number of Participants With Brachyury-Specific T-cell Responses | IFN gamma + CD8 T-cell response | 3 Participants |
| 40 YU (Dose Level 3) | Number of Participants With Brachyury-Specific T-cell Responses | IL2 + CD8 T-cell response | 0 Participants |
| 40 YU (Dose Level 3) | Number of Participants With Brachyury-Specific T-cell Responses | Any T-cell response | 8 Participants |
| 40 YU (Dose Level 3) | Number of Participants With Brachyury-Specific T-cell Responses | IFN gamma + CD4 T-cell response | 3 Participants |
| 40 YU (Dose Level 3) | Number of Participants With Brachyury-Specific T-cell Responses | IL2 + CD4 T-cell response | 3 Participants |
| 40 YU (Dose Level 3) | Number of Participants With Brachyury-Specific T-cell Responses | TNF alpha + CD4 T-cell response | 6 Participants |
| 80 YU (Dose Level 4) | Number of Participants With Brachyury-Specific T-cell Responses | CD107a + CD4 T-cell response | 1 Participants |
| 80 YU (Dose Level 4) | Number of Participants With Brachyury-Specific T-cell Responses | IFN gamma + CD4 T-cell response | 2 Participants |
| 80 YU (Dose Level 4) | Number of Participants With Brachyury-Specific T-cell Responses | TNF alpha + CD4 T-cell response | 2 Participants |
| 80 YU (Dose Level 4) | Number of Participants With Brachyury-Specific T-cell Responses | Any T-cell response | 7 Participants |
| 80 YU (Dose Level 4) | Number of Participants With Brachyury-Specific T-cell Responses | TNF alpha + CD8 T-cell response | 3 Participants |
| 80 YU (Dose Level 4) | Number of Participants With Brachyury-Specific T-cell Responses | CD107a + CD8 T-cell response | 4 Participants |
| 80 YU (Dose Level 4) | Number of Participants With Brachyury-Specific T-cell Responses | IL2 + CD8 T-cell response | 1 Participants |
| 80 YU (Dose Level 4) | Number of Participants With Brachyury-Specific T-cell Responses | IFN gamma + CD8 T-cell response | 2 Participants |
| 80 YU (Dose Level 4) | Number of Participants With Brachyury-Specific T-cell Responses | IL2 + CD4 T-cell response | 3 Participants |
Secondary
Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC)
Blood samples will be collected via apheresis and analyzed by multicolor flow cytometry in PBMCs for cluster of differentiation 4 (CD4), cluster of differentiation 8 (CD8), Natural Killer (NK), Natural Killer T (NKT), conventional dendritic cell (cDC), plasmacytoid dendritic cell (pDC), myeloid-derived suppressor cell (MDSC), Tregs, CD4 central memory (CD4 CM), CD4 effector memory (CD4 EM), CD4 terminal effector memory (CD4 EMRA), CD4 naïve, CD8 CM, CD8 EM, CD8 EMRA, and CD8 naïve cells. Significance of changes in immune cells was determined by p value (Wilcoxon test) and the median and interquartile range of data.
Time frame: Pre (Baseline) and Day 85 after 6 vaccinations
Population: Due to insufficient samples at some time points in some patients, all participants were not analyzed in dose levels 2, 3 and 4; thus a statistical analysis was not performed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 EMRA d85 | 0.34 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Natural Killer T cell (NKT) d85 | 1.25 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median pDC Pre | 0.25 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 EMRA Pre | 3.01 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 EM Pre | 3.20 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 d85 | 38.61 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median pDC d85 | 0.32 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 CM Pre | 17.29 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Natural Killer T cell (NKT) Pre | 1.00 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median MDSC Pre | 10.98 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Natural Killer (NK) d85 | 5.72 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 d85 | 15.67 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 Pre | 15.87 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median MDSC d85 | 11.41 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 naive Pre | 10.28 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 CM Pre | 1.03 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Treg Pre | 0.77 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 EMRA Pre | 0.32 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Treg d85 | 0.81 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 naive d85 | 8.48 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median B cells Pre | 7.05 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 EM d85 | 3.44 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 EM Pre | 10.58 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median cDC Pre | 0.25 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 CM d85 | 1.31 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 naive Pre | 3.47 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 EM d85 | 8.92 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Natural Killer (NK) Pre | 5.21 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 CM d85 | 18.80 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median B cells d85 | 6.93 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 Pre | 37.70 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median cDC d85 | 0.18 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 naive d85 | 3.28 percentage of PBMC |
| 4 YU (Dose Level 1) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 EMRA d85 | 2.84 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 EMRA Pre | 0.68 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 EMRA d85 | 0.83 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 CM Pre | 1.05 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 naive Pre | 7.57 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 CM Pre | 23.20 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 naive d85 | 5.41 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 EM Pre | 2.70 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Natural Killer (NK) Pre | 6.57 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 EM d85 | 3.33 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 CM d85 | 0.86 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 EMRA Pre | 2.51 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Natural Killer (NK) d85 | 8.41 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 d85 | 33.44 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Treg Pre | 0.90 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Natural Killer T cell (NKT) d85 | 2.46 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median cDC Pre | 0.14 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 Pre | 43.57 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median MDSC d85 | 10.78 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median cDC d85 | 0.17 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median pDC Pre | 0.17 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 Pre | 14.77 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Natural Killer T cell (NKT) Pre | 1.70 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median pDC d85 | 0.26 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median MDSC Pre | 8.53 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 d85 | 13.63 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 naive d85 | 6.20 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Treg d85 | 0.80 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 naive Pre | 8.51 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 EM Pre | 12.09 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median B cells Pre | 11.02 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 EM d85 | 10.72 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 EMRA d85 | 3.24 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 CM d85 | 16.51 percentage of PBMC |
| 16 YU (Dose Level 2) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median B cells d85 | 9.78 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 CM d85 | 0.95 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 Pre | 29.30 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 d85 | 34.29 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median B cells d85 | 9.10 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Natural Killer (NK) Pre | 5.72 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Natural Killer T cell (NKT) Pre | 1.27 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median cDC Pre | 0.23 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median cDC d85 | 0.21 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median pDC Pre | 0.23 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median MDSC Pre | 8.47 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median MDSC d85 | 7.55 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Treg Pre | 1.25 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Treg d85 | 1.12 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 EM Pre | 13.14 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 EM d85 | 12.50 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 CM Pre | 12.36 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 CM d85 | 12.78 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 EMRA d85 | 0.28 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 naive Pre | 3.78 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 naive d85 | 3.99 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 EM d85 | 6.60 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 naive Pre | 2.43 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 naive d85 | 3.12 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 CM Pre | 1.16 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 EMRA Pre | 2.60 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 EMRA d85 | 3.31 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 Pre | 15.96 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 d85 | 15.42 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median B cells Pre | 8.97 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Natural Killer (NK) d85 | 4.22 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Natural Killer T cell (NKT) d85 | 1.19 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median pDC d85 | 0.27 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 EMRA Pre | 0.34 percentage of PBMC |
| 40 YU (Dose Level 3) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 EM Pre | 7.19 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median B cells d85 | 8.77 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 EMRA d85 | 5.06 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 EM Pre | 11.31 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Treg d85 | 1.00 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 naive Pre | 3.71 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median MDSC d85 | 12.77 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 naive d85 | 3.44 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median MDSC Pre | 13.73 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median B cells Pre | 7.82 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 Pre | 13.76 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 CM d85 | 11.36 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 d85 | 16.02 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 d85 | 27.99 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Natural Killer (NK) d85 | 9.14 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median pDC d85 | 0.23 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median pDC Pre | 0.23 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median cDC d85 | 0.19 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 naive d85 | 6.08 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Natural Killer T cell (NKT) d85 | 2.53 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 Pre | 33.58 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median cDC Pre | 0.17 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 EMRA Pre | 5.81 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Natural Killer T cell (NKT) Pre | 2.24 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 CM d85 | 0.88 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Treg Pre | 1.07 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 EM Pre | 5.23 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 CM Pre | 1.00 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD8 EM d85 | 6.11 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 naive Pre | 4.49 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 EMRA d85 | 0.38 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 EM d85 | 9.76 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median Natural Killer (NK) Pre | 5.89 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 EMRA Pre | 0.28 percentage of PBMC |
| 80 YU (Dose Level 4) | Changes in Immune Cell Subsets in Peripheral Blood Mononuclear Cells (PBMC) | Median CD4 CM Pre | 12.07 percentage of PBMC |
p-value: 0.5221Wilcoxon test
p-value: 0.25Wilcoxon test
p-value: 0.5Wilcoxon test
p-value: 0.16Wilcoxon test
p-value: 0.8665Wilcoxon test
p-value: 0.88Wilcoxon test
p-value: 0.84Wilcoxon test
p-value: 0.57Wilcoxon test
p-value: 0.3052Wilcoxon test
p-value: >0.9999Wilcoxon test
p-value: 0.13Wilcoxon test
p-value: 0.65Wilcoxon test
p-value: 0.0698Wilcoxon test
p-value: 0.63Wilcoxon test
p-value: 0.74Wilcoxon test
p-value: 0.13Wilcoxon test
p-value: 0.0127Wilcoxon test
p-value: 0.63Wilcoxon test
p-value: 0.41Wilcoxon test
p-value: 0.07Wilcoxon test
p-value: 0.0654Wilcoxon test
p-value: 0.38Wilcoxon test
p-value: 0.21Wilcoxon test
p-value: 0.16Wilcoxon test
p-value: 0.0457Wilcoxon test
p-value: 0.63Wilcoxon test
p-value: 0.55Wilcoxon test
p-value: 0.13Wilcoxon test
p-value: 0.7114Wilcoxon test
p-value: >0.9999Wilcoxon test
p-value: 0.38Wilcoxon test
p-value: 0.91Wilcoxon test
p-value: 0.2666Wilcoxon test
p-value: 0.88Wilcoxon test
p-value: 0.45Wilcoxon test
p-value: 0.36Wilcoxon test
p-value: 0.0076Wilcoxon test
p-value: 0.38Wilcoxon test
p-value: 0.22Wilcoxon test
p-value: 0.1Wilcoxon test
p-value: 0.7144Wilcoxon test
p-value: 0.13Wilcoxon test
p-value: 0.06Wilcoxon test
p-value: 0.13Wilcoxon test
p-value: 0.3741Wilcoxon test
p-value: 0.63Wilcoxon test
p-value: 0.13Wilcoxon test
p-value: >0.9999Wilcoxon test
p-value: 0.3386Wilcoxon test
p-value: 0.88Wilcoxon test
p-value: 0.0215Wilcoxon test
p-value: 0.65Wilcoxon test
p-value: 0.5076Wilcoxon test
p-value: 0.63Wilcoxon test
p-value: 0.68Wilcoxon test
p-value: 0.73Wilcoxon test
p-value: 0.6577Wilcoxon test
p-value: 0.88Wilcoxon test
p-value: 0.74Wilcoxon test
p-value: 0.2Wilcoxon test
p-value: 0.6295Wilcoxon test
p-value: 0.63Wilcoxon test
p-value: >0.999Wilcoxon test
p-value: 0.36Wilcoxon test
p-value: 0.8314Wilcoxon test
p-value: 0.63Wilcoxon test
p-value: 0.64Wilcoxon test
p-value: 0.3Wilcoxon test
Secondary
Changes in Serum Levels of Cytokines
Blood samples were collected and changes in serum levels of cytokines interferon gamma (IFNg), Interleukin 10 (IL-10), Interleukin 12 (IL-12)p70, Interleukin 1b (IL-1b), Interleukin 2 (IL-2), Interleukin 6 (IL-6), Interleukin 8 (IL-8), and tumor necrosis factor (TNF) were assessed by the multiplexed mesoscale assay. Significance of changes in serum levels of cytokines was determined by p value (Wilcoxon test) and the median and interquartile range of data.
Time frame: Pre (Baseline) and Day 85 after 6 vaccinations
Population: Due to insufficient samples at some time points in some patients, all participants were not analyzed in dose levels 2, 3 and 4; thus a statistical analysis was not performed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 4 YU (Dose Level 1) | Changes in Serum Levels of Cytokines | Median IL-12p70 Pre | 0.2 pg/ml |
| 4 YU (Dose Level 1) | Changes in Serum Levels of Cytokines | Median IFNg Pre | 3.63 pg/ml |
| 4 YU (Dose Level 1) | Changes in Serum Levels of Cytokines | Median IL-1b Pre | 0.24 pg/ml |
| 4 YU (Dose Level 1) | Changes in Serum Levels of Cytokines | Median IL-1b d85 | 0.24 pg/ml |
| 4 YU (Dose Level 1) | Changes in Serum Levels of Cytokines | Median IL-2 Pre | 0.64 pg/ml |
| 4 YU (Dose Level 1) | Changes in Serum Levels of Cytokines | Median IL-2 d85 | 0.64 pg/ml |
| 4 YU (Dose Level 1) | Changes in Serum Levels of Cytokines | Median IL-6 Pre | 0.88 pg/ml |
| 4 YU (Dose Level 1) | Changes in Serum Levels of Cytokines | Median TNF Pre | 1.54 pg/ml |
| 4 YU (Dose Level 1) | Changes in Serum Levels of Cytokines | Median IL-6 d85 | 0.97 pg/ml |
| 4 YU (Dose Level 1) | Changes in Serum Levels of Cytokines | Median IFNg d85 | 2.64 pg/ml |
| 4 YU (Dose Level 1) | Changes in Serum Levels of Cytokines | Median IL-10 Pre | 0.24 pg/ml |
| 4 YU (Dose Level 1) | Changes in Serum Levels of Cytokines | Median IL-10 d85 | 0.26 pg/ml |
| 4 YU (Dose Level 1) | Changes in Serum Levels of Cytokines | Median IL-12p70 d85 | 0.2 pg/ml |
| 4 YU (Dose Level 1) | Changes in Serum Levels of Cytokines | Median IL-8 Pre | 56.45 pg/ml |
| 4 YU (Dose Level 1) | Changes in Serum Levels of Cytokines | Median IL-8 d85 | 33.29 pg/ml |
| 4 YU (Dose Level 1) | Changes in Serum Levels of Cytokines | Median TNF d85 | 1.63 pg/ml |
| 16 YU (Dose Level 2) | Changes in Serum Levels of Cytokines | Median IL-8 Pre | 43.87 pg/ml |
| 16 YU (Dose Level 2) | Changes in Serum Levels of Cytokines | Median IL-10 Pre | 0.215 pg/ml |
| 16 YU (Dose Level 2) | Changes in Serum Levels of Cytokines | Median TNF Pre | 1.315 pg/ml |
| 16 YU (Dose Level 2) | Changes in Serum Levels of Cytokines | Median IL-12p70 Pre | 0.22 pg/ml |
| 16 YU (Dose Level 2) | Changes in Serum Levels of Cytokines | Median IL-6 d85 | 0.855 pg/ml |
| 16 YU (Dose Level 2) | Changes in Serum Levels of Cytokines | Median IL-10 d85 | 0.285 pg/ml |
| 16 YU (Dose Level 2) | Changes in Serum Levels of Cytokines | Median IL-8 d85 | 61.85 pg/ml |
| 16 YU (Dose Level 2) | Changes in Serum Levels of Cytokines | Median IL-2 Pre | 0.64 pg/ml |
| 16 YU (Dose Level 2) | Changes in Serum Levels of Cytokines | Median IL-1b d85 | 0.24 pg/ml |
| 16 YU (Dose Level 2) | Changes in Serum Levels of Cytokines | Median IFNg Pre | 3.56 pg/ml |
| 16 YU (Dose Level 2) | Changes in Serum Levels of Cytokines | Median IL-6 Pre | 0.78 pg/ml |
| 16 YU (Dose Level 2) | Changes in Serum Levels of Cytokines | Median TNF d85 | 1.465 pg/ml |
| 16 YU (Dose Level 2) | Changes in Serum Levels of Cytokines | Median IL-1b Pre | 0.24 pg/ml |
| 16 YU (Dose Level 2) | Changes in Serum Levels of Cytokines | Median IFNg d85 | 2.83 pg/ml |
| 16 YU (Dose Level 2) | Changes in Serum Levels of Cytokines | Median IL-2 d85 | 0.64 pg/ml |
| 16 YU (Dose Level 2) | Changes in Serum Levels of Cytokines | Median IL-12p70 d85 | 0.2 pg/ml |
| 40 YU (Dose Level 3) | Changes in Serum Levels of Cytokines | Median IL-8 Pre | 37.49 pg/ml |
| 40 YU (Dose Level 3) | Changes in Serum Levels of Cytokines | Median IL-2 d85 | 0.64 pg/ml |
| 40 YU (Dose Level 3) | Changes in Serum Levels of Cytokines | Median IL-8 d85 | 43.27 pg/ml |
| 40 YU (Dose Level 3) | Changes in Serum Levels of Cytokines | Median TNF d85 | 1.67 pg/ml |
| 40 YU (Dose Level 3) | Changes in Serum Levels of Cytokines | Median IFNg Pre | 2.805 pg/ml |
| 40 YU (Dose Level 3) | Changes in Serum Levels of Cytokines | Median IFNg d85 | 2.84 pg/ml |
| 40 YU (Dose Level 3) | Changes in Serum Levels of Cytokines | Median TNF Pre | 1.62 pg/ml |
| 40 YU (Dose Level 3) | Changes in Serum Levels of Cytokines | Median IL-10 Pre | 0.21 pg/ml |
| 40 YU (Dose Level 3) | Changes in Serum Levels of Cytokines | Median IL-12p70 Pre | 0.2 pg/ml |
| 40 YU (Dose Level 3) | Changes in Serum Levels of Cytokines | Median IL-1b d85 | 0.24 pg/ml |
| 40 YU (Dose Level 3) | Changes in Serum Levels of Cytokines | Median IL-2 Pre | 0.64 pg/ml |
| 40 YU (Dose Level 3) | Changes in Serum Levels of Cytokines | Median IL-6 Pre | 1.02 pg/ml |
| 40 YU (Dose Level 3) | Changes in Serum Levels of Cytokines | Median IL-6 d85 | 1.04 pg/ml |
| 40 YU (Dose Level 3) | Changes in Serum Levels of Cytokines | Median IL-10 d85 | 0.24 pg/ml |
| 40 YU (Dose Level 3) | Changes in Serum Levels of Cytokines | Median IL-12p70 d85 | 0.2 pg/ml |
| 40 YU (Dose Level 3) | Changes in Serum Levels of Cytokines | Median IL-1b Pre | 0.24 pg/ml |
| 80 YU (Dose Level 4) | Changes in Serum Levels of Cytokines | Median TNF Pre | 3.59 pg/ml |
| 80 YU (Dose Level 4) | Changes in Serum Levels of Cytokines | Median IL-10 Pre | 0.4 pg/ml |
| 80 YU (Dose Level 4) | Changes in Serum Levels of Cytokines | Median IL-1b Pre | 0.24 pg/ml |
| 80 YU (Dose Level 4) | Changes in Serum Levels of Cytokines | Median IL-1b d85 | 0.24 pg/ml |
| 80 YU (Dose Level 4) | Changes in Serum Levels of Cytokines | Median IFNg Pre | 4.47 pg/ml |
| 80 YU (Dose Level 4) | Changes in Serum Levels of Cytokines | Median IL-10 d85 | 0.4 pg/ml |
| 80 YU (Dose Level 4) | Changes in Serum Levels of Cytokines | Median IFNg d85 | 4.9 pg/ml |
| 80 YU (Dose Level 4) | Changes in Serum Levels of Cytokines | Median IL-8 Pre | 63.52 pg/ml |
| 80 YU (Dose Level 4) | Changes in Serum Levels of Cytokines | Median IL-12p70 d85 | 0.2 pg/ml |
| 80 YU (Dose Level 4) | Changes in Serum Levels of Cytokines | Median TNF d85 | 2.74 pg/ml |
| 80 YU (Dose Level 4) | Changes in Serum Levels of Cytokines | Median IL-6 d85 | 2.84 pg/ml |
| 80 YU (Dose Level 4) | Changes in Serum Levels of Cytokines | Median IL-12p70 Pre | 0.2 pg/ml |
| 80 YU (Dose Level 4) | Changes in Serum Levels of Cytokines | Median IL-8 d85 | 73.21 pg/ml |
| 80 YU (Dose Level 4) | Changes in Serum Levels of Cytokines | Median IL-2 d85 | 0.64 pg/ml |
| 80 YU (Dose Level 4) | Changes in Serum Levels of Cytokines | Median IL-2 Pre | 0.64 pg/ml |
| 80 YU (Dose Level 4) | Changes in Serum Levels of Cytokines | Median IL-6 Pre | 2.37 pg/ml |
p-value: >0.9999Wilcoxon test
p-value: 0.5Wilcoxon test
p-value: >0.9999Wilcoxon test
p-value: 0.375Wilcoxon test
p-value: 0.4808Wilcoxon test
p-value: 0.7334Wilcoxon test
p-value: 0.7109Wilcoxon
p-value: 0.4347Wilcoxon test
p-value: >0.9999Wilcoxon
p-value: 0.748Wilcoxon test
p-value: 0.8203Wilcoxon test
p-value: 0.5625Wilcoxon test
p-value: >0.9999Wilcoxon test
p-value: >0.9999Wilcoxon test
p-value: 0.5Wilcoxon test
p-value: 0.6846Wilcoxon test
p-value: 0.4375Wilcoxon test
p-value: >0.9999Wilcoxon test
p-value: >0.9999Wilcoxon test
p-value: 0.75Wilcoxon test
p-value: 0.4525Wilcoxon test
p-value: 0.875Wilcoxon test
Comparison: Significance was met if the unadjusted p-value was \<0.05 and \>1/2 of patients had a serum level change of \>25%.p-value: 0.4316Wilcoxon test
p-value: >0.9999Wilcoxon test
p-value: 0.9906Wilcoxon test
p-value: 0.625Wilcoxon test
p-value: 0.791Wilcoxon test
p-value: 0.8203Wilcoxon test
p-value: >0.9999Wilcoxon test
p-value: 0.875Wilcoxon test
p-value: 0.9658Wilcoxon test
p-value: 0.6523Wilcoxon test
Secondary
Changes in Soluble Cluster of Differentiation 27 (sCD27)
Blood samples were collected and changes in serum levels of soluble sCD27 were assessed by enzyme-linked immunosorbent assay (ELISA). Significance of changes in soluble sCD27 was determined by p value (Wilcoxon test) and the median and interquartile range of data.
Time frame: Pre (Baseline) and Day 85 after 6 vaccinations
Population: Due to insufficient samples at some time points in some patients, all participants were not analyzed in dose levels 2, 3 and 4; thus a statistical analysis was not performed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 4 YU (Dose Level 1) | Changes in Soluble Cluster of Differentiation 27 (sCD27) | Median sCD27 Pre | 99.07 U/ml |
| 4 YU (Dose Level 1) | Changes in Soluble Cluster of Differentiation 27 (sCD27) | Median sCD27 d85 | 97.17 U/ml |
| 16 YU (Dose Level 2) | Changes in Soluble Cluster of Differentiation 27 (sCD27) | Median sCD27 d85 | 92.07 U/ml |
| 16 YU (Dose Level 2) | Changes in Soluble Cluster of Differentiation 27 (sCD27) | Median sCD27 Pre | 98.63 U/ml |
| 40 YU (Dose Level 3) | Changes in Soluble Cluster of Differentiation 27 (sCD27) | Median sCD27 d85 | 101.7 U/ml |
| 40 YU (Dose Level 3) | Changes in Soluble Cluster of Differentiation 27 (sCD27) | Median sCD27 Pre | 97.47 U/ml |
| 80 YU (Dose Level 4) | Changes in Soluble Cluster of Differentiation 27 (sCD27) | Median sCD27 Pre | 128.4 U/ml |
| 80 YU (Dose Level 4) | Changes in Soluble Cluster of Differentiation 27 (sCD27) | Median sCD27 d85 | 133.1 U/ml |
p-value: 0.0742Wilcoxon test
p-value: 0.2901Wilcoxon test
p-value: 0.375Wilcoxon test
p-value: 0.2036Wilcoxon test
Secondary
Changes in Soluble Cluster of Differentiation 40L (sCD40L)
Blood samples were collected and changes in serum levels of soluble sCD27 were assessed by enzyme-linked immunosorbent assay (ELISA). Significance of changes in soluble sCD40L was determined by p value (Wilcoxon test) and the median and interquartile range of data.
Time frame: Pre (Baseline) and Day 85 after 6 vaccinations
Population: Due to insufficient samples at some time points in some patients, all participants were not analyzed in dose levels 2, 3 and 4; thus a statistical analysis was not performed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 4 YU (Dose Level 1) | Changes in Soluble Cluster of Differentiation 40L (sCD40L) | Median sCD40L Pre | 15.3 ng/ml |
| 4 YU (Dose Level 1) | Changes in Soluble Cluster of Differentiation 40L (sCD40L) | Median sCD40L d85 | 15.23 ng/ml |
| 16 YU (Dose Level 2) | Changes in Soluble Cluster of Differentiation 40L (sCD40L) | Median sCD40L d85 | 11.14 ng/ml |
| 16 YU (Dose Level 2) | Changes in Soluble Cluster of Differentiation 40L (sCD40L) | Median sCD40L Pre | 10.24 ng/ml |
| 40 YU (Dose Level 3) | Changes in Soluble Cluster of Differentiation 40L (sCD40L) | Median sCD40L Pre | 9.648 ng/ml |
| 40 YU (Dose Level 3) | Changes in Soluble Cluster of Differentiation 40L (sCD40L) | Median sCD40L d85 | 9.854 ng/ml |
| 80 YU (Dose Level 4) | Changes in Soluble Cluster of Differentiation 40L (sCD40L) | Median sCD40L Pre | 14.72 ng/ml |
| 80 YU (Dose Level 4) | Changes in Soluble Cluster of Differentiation 40L (sCD40L) | Median sCD40L d85 | 18.57 ng/ml |
p-value: 0.0621Wilcoxon test
p-value: 0.875Wilcoxon test
p-value: 0.2402Wilcoxon test
p-value: 0.3008Wilcoxon test
Secondary
Median Ratio of Soluble Cluster of Differentiation 27:40L (sCD27:sCD40L)
Blood samples were collected and changes in serum levels of the ratio of soluble sCD27:sCD40L was assessed by enzyme-linked immunosorbent assay (ELISA). Significance of changes in soluble sCD27:sCD40L was determined by p value (Wilcoxon test) and the median and interquartile range of data.
Time frame: Pre (Baseline) and Day 85 after 6 vaccinations
Population: Due to insufficient samples at some time points in some patients, all participants were not analyzed in dose levels 2, 3 and 4; thus a statistical analysis was not performed.
| Arm | Measure | Group | Value (MEDIAN) |
|---|---|---|---|
| 4 YU (Dose Level 1) | Median Ratio of Soluble Cluster of Differentiation 27:40L (sCD27:sCD40L) | Median sCD27:sCD40L Pre | 5.982 Ratio |
| 4 YU (Dose Level 1) | Median Ratio of Soluble Cluster of Differentiation 27:40L (sCD27:sCD40L) | Median sCD27:sCD40L d85 | 6.428 Ratio |
| 16 YU (Dose Level 2) | Median Ratio of Soluble Cluster of Differentiation 27:40L (sCD27:sCD40L) | Median sCD27:sCD40L Pre | 9.57 Ratio |
| 16 YU (Dose Level 2) | Median Ratio of Soluble Cluster of Differentiation 27:40L (sCD27:sCD40L) | Median sCD27:sCD40L d85 | 8.294 Ratio |
| 40 YU (Dose Level 3) | Median Ratio of Soluble Cluster of Differentiation 27:40L (sCD27:sCD40L) | Median sCD27:sCD40L d85 | 10.47 Ratio |
| 40 YU (Dose Level 3) | Median Ratio of Soluble Cluster of Differentiation 27:40L (sCD27:sCD40L) | Median sCD27:sCD40L Pre | 9.571 Ratio |
| 80 YU (Dose Level 4) | Median Ratio of Soluble Cluster of Differentiation 27:40L (sCD27:sCD40L) | Median sCD27:sCD40L Pre | 8.57 Ratio |
| 80 YU (Dose Level 4) | Median Ratio of Soluble Cluster of Differentiation 27:40L (sCD27:sCD40L) | Median sCD27:sCD40L d85 | 8.257 Ratio |
p-value: 0.1004Wilcoxon test
p-value: 0.625Wilcoxon test
p-value: 0.6772Wilcoxon test
p-value: 0.3008Wilcoxon test
Secondary
Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST)
Clinical benefit is defined as partial response (PR) or stable disease (SD) and was assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Partial response is ≥30% decrease in the sum of greatest diameters/no new lesions. Progressive disease is ≥20% increase in the sum of greatest diameters/new lesions. Stable disease does not meet criteria for complete response (disappearance of all lesions; no new lesions), partial response, or progressive disease.
Time frame: 3 and 5 months restaging
Population: One participant was not evaluable and came off study due to infection prior to restaging. Two participants were not evaluable due to withdrawal from the study or lack of measurable disease. Three patients with stable disease at 3 months elected to pursue alternate treatment and did not have 5 month restaging.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| 4 YU (Dose Level 1) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Stable disease at 3 months | 3 Participants |
| 4 YU (Dose Level 1) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Progressive disease at 3 months | 1 Participants |
| 4 YU (Dose Level 1) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Partial response at 5 months | 0 Participants |
| 4 YU (Dose Level 1) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Progressive disease at 5 months | 1 Participants |
| 4 YU (Dose Level 1) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Stable disease at 5 months | 2 Participants |
| 4 YU (Dose Level 1) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Partial response at 3 months | 0 Participants |
| 16 YU (Dose Level 2) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Progressive disease at 5 months | 0 Participants |
| 16 YU (Dose Level 2) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Stable disease at 5 months | 0 Participants |
| 16 YU (Dose Level 2) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Partial response at 5 months | 0 Participants |
| 16 YU (Dose Level 2) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Progressive disease at 3 months | 3 Participants |
| 16 YU (Dose Level 2) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Stable disease at 3 months | 0 Participants |
| 16 YU (Dose Level 2) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Partial response at 3 months | 0 Participants |
| 40 YU (Dose Level 3) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Progressive disease at 5 months | 3 Participants |
| 40 YU (Dose Level 3) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Partial response at 5 months | 1 Participants |
| 40 YU (Dose Level 3) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Stable disease at 5 months | 4 Participants |
| 40 YU (Dose Level 3) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Partial response at 3 months | 0 Participants |
| 40 YU (Dose Level 3) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Stable disease at 3 months | 8 Participants |
| 40 YU (Dose Level 3) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Progressive disease at 3 months | 8 Participants |
| 80 YU (Dose Level 4) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Stable disease at 5 months | 3 Participants |
| 80 YU (Dose Level 4) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Progressive disease at 5 months | 0 Participants |
| 80 YU (Dose Level 4) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Partial response at 5 months | 0 Participants |
| 80 YU (Dose Level 4) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Partial response at 3 months | 0 Participants |
| 80 YU (Dose Level 4) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Stable disease at 3 months | 6 Participants |
| 80 YU (Dose Level 4) | Number of Participants With a Clinical Benefit Assessed by the Response Evaluation Criteria in Solid Tumors (RECIST) | Progressive disease at 3 months | 5 Participants |